AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2493897 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets in 24 hours)
Number of subjects: 64
Study 4931824 — intervention group
Group type: EXPERIMENTAL
Intervention: LB 46 (prinodolol)
Number of subjects: 0
Study 4931824 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 31789981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular cooling
Number of subjects: 934
Study 31789981 — intervention group
Group type: COMPARATOR
Intervention: Surface cooling
Number of subjects: 934
Study 31264510 — intervention group
Group type: COMPARATOR
Intervention: PF-06412562 45 mg
Number of subjects: 95
Study 31264510 — intervention group
Group type: COMPARATOR
Intervention: PF-06412562 (3 mg, 9 mg, 45 mg)
Number of subjects: 95
Study 28364099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg/kg loading dose for 10 min followed by 0.5 μg/(kg.h) during OLV)
Number of subjects: 56
Study 28364099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 56
Study 28364099 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 56
Study 25645599 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (15 minutes daily)
Number of subjects: 161
Study 25645599 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 161
Study 25645599 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 161
Study 24344708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis group (self-hypnosis training)
Number of subjects: 1222
Study 24344708 — intervention group
Group type: COMPARATOR
Intervention: Relaxation group (relaxation methods and Mindfulness)
Number of subjects: 1222
Study 24344708 — intervention group
Group type: COMPARATOR
Intervention: Care as usual group (ordinary antenatal care)
Number of subjects: 1222
Study 21336094 — intervention group
Group type: EXPERIMENTAL
Intervention: E-MA-H low dose (HLD)
Number of subjects: 147
Study 21336094 — intervention group
Group type: EXPERIMENTAL
Intervention: E-MA-H high dose (HHD)
Number of subjects: 147
Study 21336094 — intervention group
Group type: EXPERIMENTAL
Intervention: E-MA-HP (HP)
Number of subjects: 147
Study 21336094 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 147
Study 19859560 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E)
Number of subjects: 180
Study 19859560 — intervention group
Group type: COMPARATOR
Intervention: RTS,S/AS02(D)
Number of subjects: 180
Study 16675365 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention by social workers
Number of subjects: 194
Study 16675365 — intervention group
Group type: COMPARATOR
Intervention: General practitioners' usual care
Number of subjects: 194
Study 15249511 — intervention group
Group type: EXPERIMENTAL
Intervention: High-AGE diet (HAGE)
Number of subjects: 24
Study 15249511 — intervention group
Group type: COMPARATOR
Intervention: Low-AGE diet (LAGE)
Number of subjects: 24
Study 15249511 — intervention group
Group type: COMPARATOR
Intervention: Native LDL
Number of subjects: 24
Study 11421839 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg hyperbaric bupivacaine injected through a 24G Sprotte needle, sitting for 1 min before supine position
Number of subjects: 60
Study 11421839 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg hyperbaric bupivacaine injected through a 27G Whitacre needle, sitting for 1 min before supine position
Number of subjects: 60
Study 11421839 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg hyperbaric bupivacaine injected through a 24G Sprotte needle, sitting for 4 min before supine position
Number of subjects: 60
Study 11421839 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg hyperbaric bupivacaine injected through a 27G Whitacre needle, sitting for 4 min before supine position
Number of subjects: 60
Study 9269605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ciprofloxacin
Number of subjects: 63
Study 9269605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 63
Study 9269605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% norfloxacin
Number of subjects: 63
Study 9269605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ciprofloxacin (short-term)
Number of subjects: 63
Study 9269605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin (short-term)
Number of subjects: 63
Study 9269605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% norfloxacin (short-term)
Number of subjects: 63
Study 8507053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystography for any degree of hematuria or diagnosis of pelvic fracture
Number of subjects: 26
Study 8507053 — intervention group
Group type: COMPARATOR
Intervention: Cystography only for the presence of gross hematuria
Number of subjects: 26
Study 8507053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystography for gross hematuria
Number of subjects: 26
Study 2939715 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 to 75 mg daily, or up to 150 mg per day for longer-term use)
Number of subjects: 0
Study 2939715 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study 2939715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29848412 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise programme (4-month moderate- to high-intensity), supervised in groups, with support for unsupervised activity thereafter.
Number of subjects: 494
Study 29848412 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 494
Study 27846170 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS‐TEP after previous inguinal hernia repair
Number of subjects: 372
Study 27846170 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard procedure)
Number of subjects: 372
Study 24846621 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 coaching calls
Number of subjects: 560
Study 24846621 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 coaching calls
Number of subjects: 560
Study 24846621 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports sent to primary care physician (Yes)
Number of subjects: 560
Study 24846621 — intervention group
Group type: COMPARATOR
Intervention: Reports sent to primary care physician (No)
Number of subjects: 560
Study 24846621 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (Yes)
Number of subjects: 560
Study 24846621 — intervention group
Group type: COMPARATOR
Intervention: Text messaging (No)
Number of subjects: 560
Study 24846621 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacement recommendations (Yes)
Number of subjects: 560
Study 24846621 — intervention group
Group type: COMPARATOR
Intervention: Meal replacement recommendations (No)
Number of subjects: 560
Study 24846621 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of a participant's self‐selected support buddy (Yes)
Number of subjects: 560
Study 24846621 — intervention group
Group type: COMPARATOR
Intervention: Training of a participant's self‐selected support buddy (No)
Number of subjects: 560
Study 21837478 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise for 6 months
Number of subjects: 348
Study 20231232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenient rate-control strategy (resting heart rate <110 bpm)
Number of subjects: 614
Study 20231232 — intervention group
Group type: COMPARATOR
Intervention: Strict rate-control strategy (resting heart rate <80 bpm and heart rate during moderate exercise <110 bpm)
Number of subjects: 614
Study 20231232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenient rate-control strategy
Number of subjects: 614
Study 18802363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 5,000 IU/week
Number of subjects: 87
Study 18802363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 20,000 IU/week
Number of subjects: 87
Study 18802363 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 87
Study 16122653 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromolar grafts
Number of subjects: 57
Study 16122653 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior pelvic grafts
Number of subjects: 57
Study 16122653 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pelvic grafts
Number of subjects: 57
Study 14534520 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampin
Number of subjects: 9
Study 14534520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11214778 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 9
Study 11214778 — intervention group
Group type: COMPARATOR
Intervention: Orange juice (control)
Number of subjects: 9
Study 8895942 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomethadone maintenance therapy
Number of subjects: 42
Study 8895942 — intervention group
Group type: COMPARATOR
Intervention: Drug-free placebo control group
Number of subjects: 42
Study 1999634 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 24
Study 1999634 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 24
Study 6375799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1)
Number of subjects: 30
Study 6375799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30198318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 21
Study 30198318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 21
Study 30382877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training
Number of subjects: 300
Study 30382877 — intervention group
Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 300
Study 27251956 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L (levobupivacaine and fentanyl)
Number of subjects: 60
Study 27251956 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (Group S)
Number of subjects: 60
Study 24706299 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Number of subjects: 595
Study 21342456 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (50 g, 264 kcal)
Number of subjects: 163
Study 21342456 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (25 g, 130 kcal)
Number of subjects: 163
Study 21342456 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy flour (71 g, 282 kcal)
Number of subjects: 163
Study 19967459 — intervention group
Group type: EXPERIMENTAL
Intervention: False-negative sentinel lymph node biopsy (FN SLN)
Number of subjects: 2451
Study 19967459 — intervention group
Group type: EXPERIMENTAL
Intervention: True-positive sentinel lymph node biopsy (TP SLN)
Number of subjects: 2451
Study 19967459 — intervention group
Group type: EXPERIMENTAL
Intervention: True-negative sentinel lymph node biopsy (TN SLN)
Number of subjects: 2451
Study 19967459 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in TN group
Number of subjects: 2451
Study 19967459 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in TP group
Number of subjects: 2451
Study 19967459 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in FN group
Number of subjects: 2451
Study 19967459 — intervention group
Group type: COMPARATOR
Intervention: Comparison of overall survival between TP and FN groups
Number of subjects: 2451
Study 17336026 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Number of subjects: 99
Study 17336026 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 99
Study 15746824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group attended a 40‐hour educational course over a 4‐week period
Number of subjects: 337
Study 15746824 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 337
Study 12975259 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 2402
Study 12975259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2402
Study 10648308 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming (FAW)
Number of subjects: 149
Study 10648308 — intervention group
Group type: COMPARATOR
Intervention: Circulating water mattress
Number of subjects: 149
Study 8695926 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy protocol of six days
Number of subjects: 39
Study 8695926 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy protocol of one day
Number of subjects: 39
Study 1803218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertext browsing with computer assistance
Number of subjects: 21
Study 1803218 — intervention group
Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 21
Study 1803218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertext browsing
Number of subjects: 21
Study 6196073 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide (thiazide treatment)
Number of subjects: 324
Study 6196073 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide (long term treatment)
Number of subjects: 324
Study 6196073 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide with potassium supplements (long term treatment)
Number of subjects: 324
Study 6196073 — intervention group
Group type: COMPARATOR
Intervention: Placebo (long term treatment)
Number of subjects: 324
Study 6196073 — intervention group
Group type: EXPERIMENTAL
Intervention: Both studies pooled data
Number of subjects: 324
Study 30688974 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy plus medical management
Number of subjects: 182
Study 30688974 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 182
Study 28129353 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchanger (HME)
Number of subjects: 41
Study 28129353 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Insulation (TI) and HME (TIHME)
Number of subjects: 41
Study 28129353 — intervention group
Group type: COMPARATOR
Intervention: Control (no TI, no HME)
Number of subjects: 41
Study 28129353 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Insulation (TI)
Number of subjects: 41
Study 25600444 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 µg misoprostol
Number of subjects: 80
Study 25600444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin B6)
Number of subjects: 80
Study 24307819 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention group
Number of subjects: 120
Study 24307819 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal education group
Number of subjects: 120
Study 24307819 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 21403978 — intervention group
Group type: EXPERIMENTAL
Intervention: H. persicum extract (500 mg/day) + atorvastatin (10 mg/day) for 8 weeks
Number of subjects: 100
Study 21403978 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (20 mg/day) for 8 weeks
Number of subjects: 100
Study 19564812 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated virosomal‐adjuvanted subunit influenza vaccine (n = 90)
Number of subjects: 180
Study 19564812 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 90)
Number of subjects: 180
Study 17127441 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 0
Study 15309549 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys (17.6 (5.8) s)
Number of subjects: 48
Study 15309549 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls (21.9 (8.2) s)
Number of subjects: 48
Study 15309549 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls (11.8 (5.5)%)
Number of subjects: 48
Study 15309549 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys (8.9 (3.7)%)
Number of subjects: 48
Study 11507355 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxycillin 1 g bid, metronidazole 500 mg bid, bismuth sub‐citrate 240 mg bid and ranitidine 300 mg bid for 1 week
Number of subjects: 240
Study 11507355 — intervention group
Group type: EXPERIMENTAL
Intervention: triple therapy without ranitidine for 2 weeks
Number of subjects: 240
Study 11507355 — intervention group
Group type: EXPERIMENTAL
Intervention: triple therapy plus ranitidine 300 mg bid for 2 weeks
Number of subjects: 240
Study 9513613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17 beta estradiol 2 mg per day
Number of subjects: 0
Study 9513613 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta estradiol 50 micrograms per day
Number of subjects: 0
Study 9513613 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg per day
Number of subjects: 0
Study 9513613 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta estradiol gel 1.5 micrograms per day
Number of subjects: 0
Study 9513613 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0
Study 9513613 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed estrogen replacement therapy (at 65 years of age)
Number of subjects: 0
Study 8498533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (BRC) 1.25 mg per os
Number of subjects: 15
Study 8498533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3591727 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquabiosorb soft elastic gelatin (SEG) capsule
Number of subjects: 12
Study 3591727 — intervention group
Group type: COMPARATOR
Intervention: modified standard‐SEG capsule
Number of subjects: 12
Study 3591727 — intervention group
Group type: COMPARATOR
Intervention: commercial tablet
Number of subjects: 12
Study 3591727 — intervention group
Group type: EXPERIMENTAL
Intervention: SEG formulation
Number of subjects: 12
Study 28272972 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution‐Focused Coaching in pediatric rehabilitation (SFC‐Peds)
Number of subjects: 5
Study 26638119 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/day)
Number of subjects: 60
Study 26638119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24892199 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual body swapping through mental rehearsal
Number of subjects: 10
Study 24892199 — intervention group
Group type: COMPARATOR
Intervention: Control group (watching the virtual body swapping training video clip)
Number of subjects: 10
Study 22219334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous colloid volume loading (11 ml kg⁻¹) during heat stress
Number of subjects: 7
Study 22219334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP) while heat stressed
Number of subjects: 7
Study 22219334 — intervention group
Group type: COMPARATOR
Intervention: Lower-body negative pressure (LBNP) while normothermic
Number of subjects: 7
Study 22219334 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume loading during heat stress
Number of subjects: 7
Study 20303444 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of DTaP‐HBV‐IPV/Hib at 12 to 23 months
Number of subjects: 0
Study 20303444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal aP priming
Number of subjects: 0
Study 18620121 — intervention group
Group type: EXPERIMENTAL
Intervention: Denoised CT images using Aujol's mathematic partial differential equation algorithm
Number of subjects: 71
Study 18620121 — intervention group
Group type: COMPARATOR
Intervention: Original CT images
Number of subjects: 71
Study 17012885 — intervention group
Group type: EXPERIMENTAL
Intervention: Active specific immunotherapy with autologous tumor cell vaccines
Number of subjects: 0
Study 17012885 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 14614670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (500 mg/day) for 2-7 days, followed by oral azithromycin (1500 mg over 3 or 5 days)
Number of subjects: 25
Study 10908823 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release metoclopramide 40 mg every 12 hours
Number of subjects: 26
Study 10908823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8694208 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol infusion at 0.1 ml.kg‐1.h‐1 for 24 h after surgery
Number of subjects: 50
Study 8694208 — intervention group
Group type: COMPARATOR
Intervention: Intralipid infusion at 0.1 ml.kg‐1.h‐1 for 24 h after surgery (Control)
Number of subjects: 50
Study 1424648 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpreserved carboxymethylcellulose (CMC) artificial tears
Number of subjects: 56
Study 1424648 — intervention group
Group type: COMPARATOR
Intervention: Preserved hydroxypropylmethylcellulose (HMC) artificial tears
Number of subjects: 56
Study 4070323 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pivmecillinam plus 250 mg pivampicillin given twice daily
Number of subjects: 350
Study 4070323 — intervention group
Group type: COMPARATOR
Intervention: 250 mg amoxycillin given 3-times daily
Number of subjects: 350
Study 31906751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg + 0.25 mcg/kg/h (group D1)
Number of subjects: 100
Study 31906751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg + 0.5 mcg/kg/h (group D2)
Number of subjects: 100
Study 31906751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg + 1 mcg/kg/h (group D3)
Number of subjects: 100
Study 31906751 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 100
Study 30485853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin (atorvastatin 60 mg/day, adjusted to 20 mg/day after 7 days)
Number of subjects: 117
Study 30485853 — intervention group
Group type: COMPARATOR
Intervention: Control (atorvastatin 20 mg/day)
Number of subjects: 117
Study 30485853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin
Number of subjects: 117
Study 30485853 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 117
Study 28302075 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (60 mg) administration
Number of subjects: 54
Study 26211002 — intervention group
Group type: COMPARATOR
Intervention: Body acupuncture (Group A)
Number of subjects: 150